Identification of Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Isolates Exhibiting hVISA/VISA Phenotypes from Clinical Samples

Authors

  • Shubham Choudhary Department of Life Sciences and Biological Sciences, IES University, Bhopal, Madhya Pradesh, INDIA.

DOI:

https://doi.org/10.55544/jrasb.5.5.8

Keywords:

MRSA, MSSA, hVISA, VISA, Vancomycin, Clinical Isolates, Antimicrobial Resistance, PAP-AUC

Abstract

This study investigates the prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) phenotypes among methicillin-resistant (MRSA) and methicillin-sensitive S. aureus (MSSA) clinical isolates collected between 2020 and 2025. Using methods including PAP-AUC, E-test macromethods, and screening on BHI agar with vancomycin, we identify phenotypic and genotypic traits associated with glycopeptide resistance. Our findings reveal significant correlations between vancomycin MICs and hVISA/VISA prevalence, emphasizing the need for enhanced diagnostic and therapeutic strategies.

Downloads

Download data is not yet available.

References

[1] Charles, P. G., Ward, P. B., Johnson, P. D., et al. (2009). Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clinical Infectious Diseases, 48(3), 295–301.

[2] Chen, T. J., Wang, Y., & Lin, C. C. (2024). Genomic insights into VISA evolution among hospital-acquired S. aureus strains. Antibiotics, 13(1), 67.

[3] Cui, L., Murakami, H., Kuwahara-Arai, K., et al. (2003). Contribution of a thickened cell wall and its glutamine nonamidated peptidoglycan to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrobial Agents and Chemotherapy, 47(9), 3060–3065.

[4] Howden, B. P., Davies, J. K., Johnson, P. D., et al. (2010). Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clinical Microbiology Reviews, 23(1), 99–139.

[5] Jansen, A. M., Baker, L., & Duong, H. T. (2023). Evaluation of commercial screening tools for hVISA detection in clinical microbiology labs. BMC Infectious Diseases, 23(1), 95.

[6] Jones, M. E., Samuels, T. M., & Katz, B. D. (2024). Outcomes in patients with hVISA bloodstream infections: A multicenter retrospective study. Journal of Antimicrobial Chemotherapy, 79(2), 412–418.

[7] Lee, Y. H., Park, M., & Kim, H. (2023). Advances in rapid diagnostic testing for multidrug-resistant Staphylococcus aureus. Frontiers in Cellular and Infection Microbiology, 13, 1182.

[8] Liu, C., Bayer, A., Cosgrove, S. E., et al. (2021). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of MRSA infections in adults and children. Clinical Infectious Diseases, 52(3), e18–e55.

[9] Mwangi, M. M., Wu, S. W., Zhou, Y., et al. (2007). Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proceedings of the National Academy of Sciences, 104(22), 9451–9456.

[10] Naim, M., Iqbal, S., & Rafiq, M. A. (2023). Molecular epidemiology of VISA and hVISA in clinical MRSA isolates from Pakistan. Microbial Drug Resistance, 29(3), 225–233.

[11] Patel, K., Shah, M., & Sharma, D. (2021). Occurrence of hVISA among MSSA strains in a tertiary care hospital: An emerging concern. Journal of Laboratory Physicians, 13(1), 23–27.

[12] Pfaller, M. A., Castanheira, M., & Sader, H. S. (2022). Vancomycin and daptomycin MIC trends among MRSA: Is MIC creep real? Journal of Clinical Microbiology, 60(5), e02649-21.

[13] Satola, S. W., Farley, M. M., & Anderson, K. F. (2011). Comparison of detection methods for hVISA. Journal of Clinical Microbiology, 49(1), 297–303.

[14] Singh, R., Kapoor, R., & Joshi, M. (2022). Prevalence of hVISA phenotype in diabetic patients: A cross-sectional study from northern India. Indian Journal of Medical Microbiology, 40(1), 41–45.

[15] Wootton, M., MacGowan, A. P., & Walsh, T. R. (2001). Comparative evaluation of methods for detecting vancomycin-intermediate Staphylococcus aureus (VISA). Journal of Antimicrobial Chemotherapy, 48(4), 527–531.

[16] Verma, S., Gupta, A., & Singh, S. (2022). A Study of Identification Listeria monocytogenes Bacteria Isolated from Raw Vegetables in Madhya Pradesh, India. Ecology, environment and conservation, 28(S 539), s543.

[17] Zhang, Y., Zhao, C., & Xu, Y. (2020). Global prevalence and distribution of hVISA and VISA: A systematic review and meta-analysis. Microbial Pathogenesis, 149, 104503.

[18] Zhao, Y., Lin, L., & Xu, J. (2024). Emerging resistance mechanisms in VISA revealed by genomic surveillance. Journal of Global Antimicrobial Resistance, 35, 79–87.

[19] Gupta V, Singla N, Chander J. (2024). "Phenotypic and Genotypic Characterization of hVISA in South India." J Lab Physicians. 16(1):12-17.

[20] Zhang Y, et al. (2024). "Screening of hVISA and VISA Using BHI-V4: A Meta-Analysis." BMC Infect Dis. 24:274.

[21] Howden BP, et al. (2020). "Detecting Glycopeptide Resistance in Staphylococcus aureus." Clin Microbiol Rev. 33(3):e00191-19.

[22] CLSI. (2023). "Performance Standards for Antimicrobial Susceptibility Testing."

[23] Sader HS, et al. (2021). "Prevalence of Vancomycin Resistance Among MRSA Bacteremia." Antimicrob Agents Chemother. 65(9):e00351-21.

[24] Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., Grayson, M. L. (2009). Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clinical Infectious Diseases, 48(4), 447–456.

[25] David, M. Z., & Daum, R. S. (2010). Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clinical Microbiology Reviews, 23(3), 616–687.

[26] Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., & Tenover, F. C. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy, 40(1), 135–136.

[27] Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P., & Grayson, M. L. (2010). Reduced vancomycin susceptibility in Staphylococcus aureus, including VISA and hVISA: Mechanisms and clinical implications. Clinical Microbiology Reviews, 23(1), 99–139.

[28] Kourtis, A. P., Hatfield, K., Baggs, J., Mu, Y., See, I., Epson, E., ... & Jernigan, J. A. (2019). Vital signs: Epidemiology and recent trends in methicillin-resistant and methicillin-susceptible Staphylococcus aureus bloodstream infections—United States. MMWR. Morbidity and Mortality Weekly Report, 68(9), 214.

[29] Satola, S. W., Farley, M. M., & Anderson, K. F. (2011). Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method. Journal of Clinical Microbiology, 49(1), 177–183.

[30] Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015). Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clinical Microbiology Reviews, 28(3), 603–661.

[31] Clinical and Laboratory Standards Institute (CLSI). (2023). Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI supplement M100.

[32] Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P., & Grayson, M. L. (2010). Reduced vancomycin susceptibility in Staphylococcus aureus, including VISA and hVISA: Mechanisms and clinical implications. Clinical Microbiology Reviews, 23(1), 99–139.

[33] Kondo, Y., Ito, T., Ma, X. X., Watanabe, S., Kreiswirth, B. N., Etienne, J., & Hiramatsu, K. (2007). Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for MRSA. Antimicrobial Agents and Chemotherapy, 51(1), 264–274.

[34] Wootton, M., Howe, R. A., Hillman, R., Walsh, T. R., & Bennett, P. M. (2001). A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. Journal of Antimicrobial Chemotherapy, 47(4), 399–403.

[35] Wootton, M., MacGowan, A. P., Walsh, T. R., Howe, R. A. (2007). Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) using the British Society for Antimicrobial Chemotherapy disc diffusion method. Journal of Antimicrobial Chemotherapy, 59(3), 657–660.

[36] Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005). Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology, 43(10), 5026–5033.

Downloads

Published

2026-10-31

How to Cite

Choudhary, S. (2026). Identification of Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Isolates Exhibiting hVISA/VISA Phenotypes from Clinical Samples. Journal for Research in Applied Sciences and Biotechnology, 5(5), 72–77. https://doi.org/10.55544/jrasb.5.5.8

Issue

Vol. 5 No. 5 (2026): October Issue

Section

Articles

License

Copyright (c) 2026 Shubham Choudhary

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.